Page 12 - Tim Crew News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tim crew. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tim Crew Today - Breaking & Trending Today

Lannett Announces FDA Acceptance, As A Priority Original ANDA, Of The Generic Advair Diskus® Filing


Lannett Announces FDA Acceptance, As A Priority Original ANDA, Of The Generic Advair Diskus® Filing
News provided by
Share this article
Share this article
PHILADELPHIA, June 1, 2021 /PRNewswire/  Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for Fluticasone Propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg), which was submitted by Lannett on behalf of its strategic alliance partner, Respirent Pharmaceuticals Co. Ltd. The FDA assigned a Generic Drug User Fee Act of 2017 (GDUFA II) goal date for this priority original ANDA of January 31, 2022.
The product is the generic equivalent of ADVAIR DISKUS ....

United States , Robert Jaffe , Advair Diskus , Flovent Diskus , Lannett Company , Drug Administration , Exchange Commission , Respirent Pharmaceuticals Co , Lannett Company Inc , Robert Jaffe Co , Abbreviated New Drug Application , Fluticasone Propionate , Respirent Pharmaceuticals , Generic Drug User Fee Act , Tim Crew , Fluticasone Propionate Powder Inhaler , Affordable Respiratory , ஒன்றுபட்டது மாநிலங்களில் , ராபர்ட் ஜாஃப் , லானெட் நிறுவனம் , பரிமாற்றம் தரகு , லானெட் நிறுவனம் இன்க் , ராபர்ட் ஜாஃப் இணை , ஜெநெரிக் மருந்து பயனர் கட்டணம் நாடகம் , நேரம் குழுவினர் ,

Lannett Company, Inc (LCI) Q1 2021 Earnings Call Transcript


Operator
Welcome to the Lannett Company s Fiscal 2021 Third Quarter Financial Results Conference Call. My name is Hilda and I will be your operator for today. Later, we will conduct a question-and-answer session. [Operator Instructions]
I will now turn the call over to Mr. Robert Jaffe, Investor Relations for Lannett. Mr. Jaffe, you may begin.
Robert Jaffe
Investor Relations for Lannett
Good afternoon, everyone, and thank you for joining us today to discuss Lannett Company s fiscal 2021 third quarter financial results. On the call today are Tim Crew, Chief Executive Officer; John Kozlowski, the company s Chief Financial Officer, Maureen Cavanaugh, our Chief Commercial Operations Officer and Steve Lehrer, who leads our insulin biosimilar initiatives. This call is being broadcast live at www.lannett.com. A playback will be available for at least three months on Lannett s website. I would like to make the cautionary statement and remind everyone that all of the ....

Matt Hewitt , Greg Gilbert , Robert Jaffe , Greg Gilbert Truist , Raymond James , Gary Nachman , Steve Lehrer , Lucas Lee , Maureen Cavanaugh , John Kozlowski , Elliot Wilbur , Lucas Lee Raymond James , Lannett Company , Kremers Urban Pharmaceuticals , Lannett Company Inc , Lannett Company Fiscal , Quarter Financial Results Conference , Investor Relations , Tim Crew , Chief Executive Officer , Chief Financial Officer , Chief Commercial Operations Officer , Safe Harbor , Litigation Reform , Accepted Accounting Principles , Metered Dose ,

Lannett Announces Fiscal 2021 Third-Quarter Financial Results


Share this article
Share this article
PHILADELPHIA, May 5, 2021 /PRNewswire/ Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 third quarter ended March 31, 2021. 
In recent months, we have significantly advanced a number of strategic initiatives, said Tim Crew, chief executive officer of Lannett. In April, we successfully completed a transaction to refinance our debt, using the proceeds to retire the outstanding Term Loan B balance of approximately $540 million that was set to mature in November of next year. As a result, we have extended the maturity of our debt to 2026 from 2022, which is after several high-value pipeline assets are expected to be commercialized. Moreover, we improved our free cash flow, by approximately $50 million in the first year alone, which we plan to use, in part, to support our growth initiatives. ....

United States , Robert Jaffe , Flovent Diskus , Lannett Company , Prnewswire Lannett Company Inc , Silarx Pharmaceuticals Inc , Kremers Urban Pharmaceuticals Inc , Exchange Commission , Recro Gainesville , Lannett Company Inc , Robert Jaffe Co , Tim Crew , Abbreviated New Drug Application , Call Information , Senior Convertible Note , Silarx Pharmaceuticals , Term Loan , Chief Financial Officer , Kremers Urban Pharmaceuticals , ஒன்றுபட்டது மாநிலங்களில் , ராபர்ட் ஜாஃப் , லானெட் நிறுவனம் , க்ரேமேர்ச் நகர்ப்புற மருந்துகள் இன்க் , பரிமாற்றம் தரகு , லானெட் நிறுவனம் இன்க் , ராபர்ட் ஜாஃப் இணை ,